We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+15.78%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$214M
AUM Growth
+$8.02M
Cap. Flow
-$22.7M
Cap. Flow %
-10.61%
Top 10 Hldgs %
48%
Holding
89
New
17
Increased
13
Reduced
25
Closed
14

Top Buys

Rank Stock Value
1
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$3.38M
2
INDP icon
Indaptus Therapeutics
INDP
+$2.82M
3
KURA icon
Kura Oncology
KURA
+$1.91M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$1.63M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$1.38M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$3.44M
2
ARGX icon
argenx
ARGX
+$2.88M
3
PODD icon
Insulet
PODD
+$2.82M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.72M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 85.47%
2 Financials 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
51
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$929K 0.44%
+23,500
New +$746K
VIRX
52
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$792K 0.37%
10,677
– –
NTGN
53
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$630K 0.3%
+50,000
New +$685K
BLUE
54
DELISTED
bluebird bio
BLUE
$628K 0.29%
+309
New +$704K
APTX
55
DELISTED
Aptinyx Inc. Common Stock
APTX
$604K 0.28%
+25,000
New +$535K
GLMD icon
56
Galmed Pharmaceuticals
GLMD
$4.62M
$595K 0.28%
+278
New +$402K
CYTK icon
57
Cytokinetics
CYTK
$10.6B
$576K 0.27%
+69,437
New +$578K
URGN icon
58
UroGen Pharma
URGN
$1.97B
$498K 0.23%
10,000
+5,500
+122% +$320K
MASI
59
DELISTED
Masimo
MASI
$488K 0.23%
5,000
– –
RIGL icon
60
Rigel Pharmaceuticals
RIGL
$723M
$389K 0.18%
13,760
-76,433
-85% -$2.72M
LCTX icon
61
Lineage Cell Therapeutics
LCTX
$264M
$374K 0.18%
207,569
– –
ONC
62
BeOne Medicines Ltd
ONC
$33.9B
$307K 0.14%
2,000
-5,330
-73% -$951K
RDUS
63
DELISTED
Radius Health, Inc.
RDUS
$295K 0.14%
+10,000
New +$316K
SLGL icon
64
Sol-Gel Technologies
SLGL
$270M
$270K 0.13%
3,500
– –
KDMN
65
DELISTED
Kadmon Holdings, Inc.
KDMN
$261K 0.12%
+65,500
New +$256K
TBIO
66
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$253K 0.12%
+20,000
New +$242K
BLCM
67
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$221K 0.1%
+3,000
New +$234K
DERM
68
DELISTED
Dermira, Inc.
DERM
$212K 0.1%
23,000
-53,000
-70% -$494K
NEOS
69
DELISTED
Neos Therapeutics, Inc
NEOS
$172K 0.08%
27,500
– –
FTSV
70
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$160K 0.07%
+10,000
New +$155K
CLSD
71
DELISTED
Clearside Biomedical
CLSD
– –
-333
Closed -$54K
COGT icon
72
Cogent Biosciences
COGT
$6.76B
– –
-1,975
Closed -$88K
NGNE icon
73
Neurogene
NGNE
$672M
– –
-5,396
Closed -$1.52M
PODD icon
74
Insulet
PODD
$11.8B
– –
-32,484
Closed -$2.82M
RCUS icon
75
Arcus Biosciences
RCUS
$3.33B
– –
-7,500
Closed -$116K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, DAFNA Capital Management held 89 positions worth $214M, up 3.9% from $206M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $22.7M in Q2 2018, closing 14 positions and reducing 25 holdings. Its most notable exit was Insulet, an estimated $2.82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Yarrow Bioscience, Inc. Common Stock worth $2.53M.

  • DAFNA Capital Management's largest Q2 2018 buy was Yarrow Bioscience, Inc. Common Stock: 87 shares worth $2.53M.
  • DAFNA Capital Management added most to Kura Oncology in Q2 2018, an estimated $1.91M increase.
  • DAFNA Capital Management's biggest Q2 2018 reduction was Loxo Oncology, Inc, cutting an estimated $3.44M.
  • DAFNA Capital Management fully exited Insulet in Q2 2018, selling an estimated $2.82M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $214M portfolio in Q2 2018.
  • DAFNA Capital Management opened 17 new positions and closed 14 in Q2 2018.
  • DAFNA Capital Management's portfolio value rose 3.9% quarter-over-quarter to $214M.

Based on DAFNA Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.